In addition, anti-CTLA4 drugs have been studied in multiple preclinical studies and clinical trials, combined with anti-PDL1 or anti-OX40 antibodies for various cancers, including NSCLC [132], prostate cancer [132], mesothelioma [133], breast cancer [132], HCC [134], and pancreatic cancer [135]. This evidence concerns the gene CD274 and Familial prostate cancer.